Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D002908: Chronic Disease

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (32)


Name (Synonyms) Correlation
drug954 Cyclosporine Wiki 0.37
drug944 Crisis management coaching Wiki 0.28
drug3431 Text message Wiki 0.28
Name (Synonyms) Correlation
drug1643 In-Person Default Wiki 0.28
drug1243 Exercise training group Wiki 0.28
drug2732 Quantitative IgG Test Wiki 0.28
drug3392 Telehealth coaching sessions Wiki 0.28
drug819 Coala Heart Monitor Wiki 0.28
drug1966 Maraviroc + Currently used therapy Wiki 0.28
drug932 Covax-19™ Wiki 0.28
drug939 Covid-19 swab PCR test Wiki 0.28
drug1794 LIIT.CI ACT Wiki 0.28
drug3941 life questionnaires Wiki 0.28
drug1837 Lifestyle intervention Wiki 0.28
drug1712 Intervention-EDI and health coaching Wiki 0.28
drug892 Control-EDI Wiki 0.28
drug1301 Favipiravir + Currently used therapy Wiki 0.28
drug936 Covid-19 Rapid Test Kit (RAPG-COV-019) Wiki 0.28
drug950 Curently used therapy for COVID-19 non-critical patients Wiki 0.28
drug940 Covid19 Wiki 0.28
drug955 CytoSorb Wiki 0.28
drug934 Covid-19 + patients Wiki 0.28
drug1190 Enhanced Chronic Disease Self-management program Wiki 0.28
drug1125 EHR-based Clinician Jumpstart Wiki 0.28
drug952 Customized questionnaire Wiki 0.28
drug3646 Video Default Wiki 0.28
drug1968 Maraviroc+Favipiravir+CT Wiki 0.28
drug168 Active Choice Wiki 0.28
drug1795 LIIT.CI CFT Wiki 0.28
drug3321 SyB V-1901 Wiki 0.28
drug4069 questionnaire Wiki 0.14
drug895 Convalescent Plasma Wiki 0.05

Correlated MeSH Terms (30)


Name (Synonyms) Correlation
D000071069 Multiple Chronic Conditions NIH 0.28
D006337 Heart Murmurs NIH 0.28
D051436 Renal Insufficiency, Chronic NIH 0.20
Name (Synonyms) Correlation
D016491 Peripheral Vascular Diseases NIH 0.20
D000073296 Noncommunicable Diseases NIH 0.20
D007674 Kidney Diseases NIH 0.17
D058729 Peripheral Arterial Disease NIH 0.16
D008269 Macular Edema NIH 0.16
D011111 Polymyalgia Rheumatica NIH 0.16
D013700 Giant Cell Arteritis NIH 0.16
D014652 Vascular Diseases NIH 0.14
D009362 Neoplasm Metastasis NIH 0.14
D008103 Liver Cirrhosis, NIH 0.14
D051437 Renal Insufficiency, NIH 0.12
D006973 Hypertension NIH 0.12
D007154 Immune System Diseases NIH 0.11
D063766 Pediatric Obesity NIH 0.11
D000066553 Problem Behavior NIH 0.10
D050177 Overweight NIH 0.10
D007676 Kidney Failure, Chronic NIH 0.10
D006333 Heart Failure NIH 0.09
D008175 Lung Neoplasms NIH 0.09
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.08
D017563 Lung Diseases, Interstitial NIH 0.08
D009103 Multiple Sclerosis NIH 0.08
D008171 Lung Diseases, NIH 0.06
D001523 Mental Disorders NIH 0.05
D002318 Cardiovascular Diseases NIH 0.05
D007249 Inflammation NIH 0.05
D009369 Neoplasms, NIH 0.05

Correlated HPO Terms (16)


Name (Synonyms) Correlation
HP:0030148 Heart murmur HPO 0.28
HP:0012622 Chronic kidney disease HPO 0.23
HP:0011505 Cystoid macular edema HPO 0.20
Name (Synonyms) Correlation
HP:0000077 Abnormality of the kidney HPO 0.18
HP:0000822 Hypertension HPO 0.14
HP:0001395 Hepatic fibrosis HPO 0.14
HP:0004950 Peripheral arterial stenosis HPO 0.12
HP:0000083 Renal insufficiency HPO 0.12
HP:0000708 Behavioral abnormality HPO 0.10
HP:0100526 Neoplasm of the lung HPO 0.10
HP:0001635 Congestive heart failure HPO 0.09
HP:0006510 Chronic pulmonary obstruction HPO 0.09
HP:0006515 Interstitial pneumonitis HPO 0.08
HP:0002088 Abnormal lung morphology HPO 0.06
HP:0002664 Neoplasm HPO 0.05
HP:0001626 Abnormality of the cardiovascular system HPO 0.05

Clinical Trials

Navigate: Correlations   HPO

There are 13 clinical trials


1 Kijk op Overgewicht Bij Kinderen: Study Regarding Etiological Factors, Risk Factors and Early Stages of Chronic Disease in Different Degrees of Childhood Overweight

Children and adolescents with overweight and obesity are predisposed to significant health problems. It is known that childhood obesity can adversely affect almost every organ system, and if left untreated, the major impact of childhood overweight is likely to be felt in the next generation of adults. The aim of " Kijk op overgewicht bij kinderen" is to collect and follow-up longitudinal data from a population of different degrees of children with overweight regarding etiological factors, risk factors and early stages of chronic disease in different degrees of childhood overweight.

NCT02091544
Conditions
  1. Childhood Obesity
Interventions
  1. Other: Lifestyle intervention
MeSH:Pediatric Obesity Overweight Chronic Disease

Primary Outcomes

Measure: The number of overweight or obese children

Time: approximately 10 years
2 Evaluate Health Coaching Support in Technology-based Interventions for Goal Setting (PEC 15-470)

In this trial, the investigators will examine whether text messages sent to Veterans will help support in meeting nutrition or physical activity health goals. All participants will get text messages over two month to support their goal.

NCT04021472
Conditions
  1. Chronic Disease Prevention
Interventions
  1. Behavioral: Text message
MeSH:Chronic Disease

Primary Outcomes

Description: Self-reported confidence in performing healthful diet and physical activity behaviors. Self-efficacy - Healthful eating via Revised Eating Self-Efficacy Scale (ESES-R). Range: 1-10; higher values represent a better outcome.

Measure: Self-efficacy: Healthful eating via Revised Eating Self-Efficacy Scale (ESES-R)

Time: Change from Baseline to 2 months

Description: Self-reported commitment to healthful diet and physical activity goals. Goal commitment - Healthful eating via the Hollenbeck, Williams, and Klein Goal Commitment Scale. Range: 1-5; higher values represent a better outcome.

Measure: Goal commitment: Healthful eating via the Hollenbeck, Williams, and Klein Goal Commitment Scale

Time: Change from Baseline to 2 months

Description: Self-reported confidence in performing healthful diet and physical activity behaviors. Self-efficacy - Physical activity via the Self-efficacy for Exercise Behaviors Scale. Range: 1-5; higher values represent a better outcome.

Measure: Self-efficacy: Physical activity via the Self-efficacy for Exercise Behaviors Scale

Time: Change from Baseline to 2 months

Description: Self-reported commitment to healthful diet and physical activity goals. Goal commitment - Physical activity via the Hollenbeck, Williams, and Klein Goal Commitment Scale. Range: 1-5; higher values represent a better outcome.

Measure: Goal commitment: Physical activity via the Hollenbeck, Williams, and Klein Goal Commitment Scale

Time: Change from Baseline to 2 months

Secondary Outcomes

Description: Self-reported confidence in patient engagement. Health Confidence. Range: 0-12; higher values represent a better outcome.

Measure: Health confidence: the Health Confidence Score

Time: Change from Baseline to 2 months
3 Controlling Hypertension Through Education and Coaching in Kidney Disease

Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.

NCT04087798
Conditions
  1. Chronic Kidney Diseases
  2. Chronic Disease
  3. Chronic Kidney Disease, Stage 3 (Moderate)
  4. Chronic Kidney Disease, Stage 4 (Severe)
  5. Chronic Kidney Disease Stage 5
Interventions
  1. Behavioral: Control-EDI
  2. Behavioral: Intervention-EDI and health coaching
MeSH:Kidney Diseases Renal Insufficiency, Chronic Hypertension Chronic Disease
HPO:Abnormality of the kidney Chronic kidney disease Hypertension Nephropathy

Primary Outcomes

Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

Measure: Change in Systolic Blood Pressure between baseline and 12 months

Time: Baseline, 12 months

Secondary Outcomes

Description: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

Measure: Change in Diastolic Blood Pressure between baseline and 12 months

Time: Baseline, 12 months

Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

Measure: Slope of systolic BP between baseline and 12 months using all available BP values

Time: Baseline up to 12 months

Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

Measure: Slope of diastolic BP between baseline and 12 months using all available BP values

Time: Baseline up to 12 months

Description: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.

Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS)

Time: Baseline up to 12 months

Description: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.

Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R)

Time: Baseline up to 12 months

Description: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.

Measure: Morisky Medication Adherence Scale (MMAS - 8)

Time: Baseline up to 12 months

Description: Length of time provider spends with the patient. This will be compared between the intervention group and control group.

Measure: Visit Time with provider

Time: Enrollment visit (baseline)

Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.

Measure: Total time in clinic

Time: Enrollment visit (baseline)

Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.

Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ)

Time: Baseline up to 12 months

Description: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.

Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT)

Time: Baseline up to 12 months

Description: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.

Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM)

Time: Baseline up to 12 months

Description: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.

Measure: Perceptions of health coaching for the intervention group

Time: Baseline up to 12 months

Description: The EMR will be reviewed to evaluate the patients medication refills for adherence.

Measure: Medication adherence from the electronic medical record (EMR)

Time: Baseline up to 12 months

Description: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.

Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS)

Time: Baseline up to 12 months

Description: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.

Measure: Self-reported Blood Pressure-Related Behaviors Survey

Time: Baseline up to 12 months

Description: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.

Measure: Provider Adoption based on EMR query and patient survey

Time: Baseline

Description: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.

Measure: Provider Fidelity measured by EMR query

Time: Baseline

Description: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.

Measure: Provider Perception of Usefulness by provider survey

Time: Baseline up to 12 months

Description: Change in Serum Creatinine between baseline and 12-months

Measure: Change in serum creatinine

Time: Baseline, 12 months

Measure: Change in urine protein-creatinine ratio

Time: Baseline, 12 months

Measure: Change in estimated glomerular filtration rate (eGFR)

Time: Baseline, 12 months
4 Using the Electronic Health Record to Identify and Promote Goals-of-Care Communication for Older Patients With Serious Illness

The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.

NCT04281784
Conditions
  1. Dementia
  2. Chronic Disease
  3. Neoplasm Metastasis
  4. Lung Neoplasm
  5. Pulmonary Disease, Chronic Obstructive
  6. Heart Failure,Congestive
  7. Liver Cirrhosis
  8. Kidney Failure, Chronic
  9. Lung Diseases, Interstitial
  10. Peripheral Vascular Disease
  11. Diabetes With End Organ Injury
  12. Palliative Care, Patient Care
  13. Health Care Quality, Access, and Evaluation
  14. Patient Care
  15. Inpatients
  16. Health Communication
  17. Patient Care Planning
Interventions
  1. Behavioral: EHR-based Clinician Jumpstart
MeSH:Neoplasms Neoplasm Metastasis Lung Neoplasms Liver Cirrhosis Lung Diseases Pulmonary Disease, Chronic Obstructive Lung Diseases, Interstitial Renal Insufficiency Kidney Failure, Chronic Heart Failure Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease Chronic Disease
HPO:Abnormal lung morphology Chronic pulmonary obstruction Cirrhosis Congestive heart failure Hepatic fibrosis Interstitial pneumonitis Interstitial pulmonary abnormality Left ventricular dysfunction Neoplasm Neoplasm of the lung Peripheral arterial stenosis Renal insufficiency Right ventricular failure

Primary Outcomes

Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.

Measure: EHR documentation of Goals of Care discussions

Time: Assessed for the period between randomization and 30 days following randomization

Secondary Outcomes

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU admissions

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU length of stay

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/Hospital use: Hospital length of stay

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: Hospital Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: ICU Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

Description: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.

Measure: Intensity of care: Healthcare costs

Time: 1 and 3 months after randomization

Description: From Washington State death certificates.

Measure: All-cause mortality at 1 year (safety outcome)

Time: 1 year after randomization

Other Outcomes

Description: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.

Measure: Key Implementation Factors

Time: 3 months after randomization
5 How Are You Coping? Assessing the Psychological, Social, and Economic Impacts of an Emerging Pandemic

A dynamic analytical tool is being implemented to monitor the health, psychosocial and economic impacts of the COVID-19 pandemic as the crisis unfolds. A longitudinal survey is distributed via a network of hospitals, provincial/national organizations and web platforms. The survey information can be linked to provincial health administrative data and metrics derived from social media activity based on artificial intelligence methods. Targeted questions are included for critical populations such as healthcare workers and people with chronic illnesses.

NCT04369690
Conditions
  1. COVID-19
  2. Chronic Disease
  3. Psychiatric Disorder
  4. Cardiovascular Diseases
MeSH:Cardiovascular Diseases Chronic Disease Mental Disorders Problem Behavior
HPO:Abnormality of the cardiovascular system Behavioral abnormality

Primary Outcomes

Description: Cohen's Perceived Stress Scale (scores ranged from 0 to 40, higher scores indicating worse stress)

Measure: Mental health - Stress

Time: through study completion, estimated to 8 months

Description: Generalized Anxiety Disorder Scale (scores ranged from 0 to 21, higher scores indicating worse anxiety)

Measure: Mental health - Anxiety

Time: through study completion, estimated to 8 months

Description: Quick Inventory of Depressive Symptomatology-Self-report, short version (scores ranged from 0 to 27, higher scores indicating worse depression)

Measure: Mental health - Depression

Time: through study completion, estimated to 8 months

Secondary Outcomes

Description: Measure of Moral Distress - Healthcare Professionals (scores ranged from 0 to 432, higher scores indicating worse moral distress)

Measure: Moral distress in healthcare workers

Time: through study completion, estimated to 8 months

Description: Rushton Moral Resilience Scale (scores ranged from 1 to 4, higher scores indicating more resiliency)

Measure: Moral resilience in healthcare workers

Time: through study completion, estimated to 8 months

Description: Frequency of interacting with other people (daily, weekly, monthly, less often than monthly)

Measure: Social life

Time: through study completion, estimated to 8 months

Description: Fever, Cough, Difficulty breathing or shortness of breath, Tiredness, Aches and pains, Nasal congestion, Runny nose, Sore throat, Diarrhea (Mild Moderate, Severe, N/A)

Measure: COVID-9 symptoms

Time: through study completion, estimated to 8 months

Description: Mortality (Yes/No): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Adverse health long-term outcome

Time: 5 years before the outbreak and two years after

Description: Hospitalizations (total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - Inpatient

Time: 5 years before the outbreak and two years after

Description: Emergency Department visits (Total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - ER

Time: 5 years before the outbreak and two years after

Description: Outpatient visits: https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - Outpatient

Time: 5 years before the outbreak and two years after

Description: Pittsburgh Sleep Quality Index (scores ranged from 0 to 21, higher scores indicating worse sleep disturbances)

Measure: Sleep

Time: through study completion, estimated to 8 months
6 COVID-19 Related Lockdown Effects On Chronic Diseases

The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.

NCT04390126
Conditions
  1. Chronic Coronary Syndrome
  2. Heart Failure
  3. AMD and Macular Edema
  4. Chronic Respiratory Failure
  5. Hemophilia
  6. Malignant Hemopathy
  7. Multiple Sclerosis
  8. Horton's Disease
Interventions
  1. Other: life questionnaires
  2. Other: questionnaire
MeSH:Polymyalgia Rheumatica Respiratory Insufficiency Multiple Sclerosis Giant Cell Arteritis Macular Edema Chronic Disease
HPO:Cystoid macular edema Macular edema

Primary Outcomes

Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)

Measure: % adherence to each pharmacological class

Time: during the period from 20 April 2020 to 7 May 2020

Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)

Measure: number of occurrence of medical events at 1 year

Time: throughout the study for 12 months

Secondary Outcomes

Description: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change

Measure: Expressed in %: Non-pharmacological treatment/lifestyle:

Time: during the period from 20 April 2020 to 7 May 2020

Measure: Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication

Time: during the period from 20 April 2020 to 7 May 2020

Measure: Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)

Time: during the period from 20 April 2020 to 7 May 2020
7 Testing the Efficacy of a Low Intensity Internet Therapy for Chronic Illness (@LIIT.CI): The Contribute of Explicit Compassion Practices in ACT

Chronic illness (CI) presents a significant and negative effect on quality of life and mental health. Further, emotion regulation has been considered of particular importance on the determination of chronic patients' well-being. Evidence suggests that Acceptance and Commitment Therapy (ACT) is an effective approach to improve psychological health in patients with CI. Further, there is some, although limited, evidence, that self-compassion training may be also useful in this context, and the inclusion of self-compassion elements in ACT interventions has even been the focus of attention by recent studies. Nevertheless, no study yet has compared the efficacy of these two types of intervention in CI. This is the aim of the present project - to analyse, in a low intensity eHealth intervention context, whether ACT or Compassion Focused Therapy (CFT) present superiority over the other in improving mental health and illness-related outcomes in CI.

NCT04408651
Conditions
  1. Chronic Medical Conditions
Interventions
  1. Behavioral: LIIT.CI ACT
  2. Behavioral: LIIT.CI CFT
MeSH:Chronic Disease

Primary Outcomes

Description: Higher scores indicate more depression and anxiety symptoms

Measure: Depression and anxiety (Hospital Anxiety and Depression Scales; HADS)

Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessments

Secondary Outcomes

Description: Higher scores indicate higher levels of illness shame

Measure: Illness shame (Chronic Illness Shame Scale; CISS)

Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessments

Description: Higher scores indicate higher levels of psychological flexibility

Measure: Psychological Flexibility (Comprehensive assessment of ACT processes; CompACT)

Time: Pre-intervention, post-intervention, and 3 and 6-month follow-ups

Description: Higher scores indicate higher levels of self-compassion (subscale of the Self-compassion scale)

Measure: Self-compassion (Self-compassion scale; SCS)

Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessments

Description: Higher scores indicate higher levels of self-cristicism (subscale of the Self-compassion scale)

Measure: Self-criticism (Self-compassion scale; SCS)

Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessments

Description: Higher scores indicate higher levels of cognitive fusion

Measure: Cognitive fusion (Cognitive Fusion Scale; CFQ-7)

Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessments

Other Outcomes

Description: Higher scores indicate more fear of contracting COVID-19

Measure: Fear of contracting COVID-19 (Fear of contracting COVID-19 scale; FCCS)

Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessments
8 Assessing Effectiveness of a Chronic Disease Self-management Program in Faith-based Organizations in Barbados: a Cluster Randomized Trial

In Barbados, levels of hypertension are high (40.7%) and cause of a high proportion of deaths due to cardiovascular diseases. In this study, the Stanford University-led Chronic Disease Self-Management Program (CDSMP) will be modified to form one of the basic components of a three-pronged intervention to improve blood pressure control. Our overall goal is to evaluate the effectiveness of a hypertension self-management program in community-based settings. With the advent of the Coronavirus disease 2019 (COVID-19) we recognize that it may be necessary to adapt the programme to accommodate virtual delivery. Our specific aims are to: 1. Adapt the Stanford (CDSMP) to ensure cultural appropriateness to Barbados. In view of the need to adhere to physical distance guidelines in the era of COVID-19 disease, modifications will be made to enhance virtual delivery while maintaining programme fidelity. We will engage stakeholders in performing modifications related to content, context and mode of delivery of the CDSMP program with the goal of ensuring cultural appropriateness. 2. Determine the clinical effectiveness of CDSMP combined with medication enhancement tools. We will conduct a cluster randomized trial in twelve faith-based organizations(FBOs) in Barbados. We are primarily interested in studying the changes in systolic blood pressure. Secondarily, we will also assess change in weight, medication adherence, dietary behavior and physical activity. 3. Understand the barriers and facilitators to implementation and sustainability of CDSMP plus self-monitoring tools in faith-based organizations. We will assess cost and sustainability of the intervention and qualitatively assess factors associated with barriers and facilitators of implementation in FBOs in Barbados. Impact and novelty: We aim to increase the proportion of patients with controlled hypertension leading to reduced illness and deaths from strokes and heart attacks in particular. Few studies have looked at a blended approach to CDSMP delivery and these will become more necessary in the era of COVID-19. Findings on the factors impacting implementation will be transferable to small island developing states and other predominantly black populations.

NCT04437966
Conditions
  1. Hypertension
Interventions
  1. Behavioral: Enhanced Chronic Disease Self-management program
MeSH:Hypertension Chronic Disease
HPO:Hypertension

Primary Outcomes

Description: We will measure systolic blood pressure before and 6 months after the interventions

Measure: Systolic blood pressure

Time: Six months

Secondary Outcomes

Description: We will measure participants' weight in kilograms before and six months after the intervention

Measure: Mean weight change for intervention and control groups

Time: Six months

Description: Changes in dietary behavior will be monitored by using the Dietary Approaches to Stop Hypertension Accordance Score. Score ranges from 0 to 9. A low score represents a poor diet for hypertension control. The higher the score the more appropriate for hypertension control.

Measure: Level of adherence to the Dietary Approaches to Stop Hypertension (DASH) Diet

Time: Six months

Description: Using the results of the GPAQ median physical activity in MET-minutes per week will be calculated before the intervention as well as six months post intervention

Measure: Assessing physical activity levels using the Global Physical Activity Questionnaire (GPAQ)

Time: Six months

Description: Perceived self-efficacy scores will be calculated using a tool developed by K Lorig(Stanford University School of Medicine) for measuring self-efficacy in chronic disease management programs. Score ranges from 1 to 10. A higher score is better.

Measure: Self-Efficacy for Managing Chronic Diseases 6-item Scale

Time: Six months
9 Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience

As of May 30th more than 23,000 cases of COVID -19 cases were confirmed in Egypt with total deaths of 913. Post viral entry, intense immune response against the virus with infiltration of monocytes and macrophages into alveolar cells with decreasing number of lymphocytes in peripheral blood along with reduced lymphocytes in lymphoid organs, hypercoagulability, thrombosis and multiple organ damage, The gut microbiota and immune homeostasis seem to have a back and forth relationship. Also, gut microbiota derived signals are known to tune the immune cells for pro and anti-inflammatory responses thereby affecting the susceptibility to various diseases. Healthy gut microbiome essentially could be pivotal in maintaining an optimal immune system to prevent an array of excessive immune reactions that eventually become detrimental to lungs and vital organ systems. Numerous studies have shown that the patient's nutritional status have a significant effect on an individual's immunity and over all health status and it has been suggested that nutritional deficiencies may predispose to severe forms of COVID-19 infections. Co-existing non-communicable chronic diseases (NCDs) in COVID-19 patients have been found to delay patients recovery and worsen their prognosis, the reason may be due to aggravated inflammatory pathology found in NCDs exacerbating COVID-19 infection. The aim of the study is to evaluate the role dietary habits among COVID-19 Egyptian patients and whether type of diet (Mediterranean or Western) will affect disease outcomes

NCT04447144
Conditions
  1. Covid19
  2. Chronic Inflammation
  3. Non-Communicable Chronic Diseases
MeSH:Inflammation Chronic Disease Noncommunicable Diseases

Primary Outcomes

Description: To assess the relation between type of diet in mild to moderate COVID 19, to the fate of their course; either improvement or progression

Measure: Western versus Mediterranean diet in COVID-19 outcome

Time: 2 months

Description: To asses any possible links between gut microbiome and the lung affecting clinical presentation of mild to moderate COVID cases; as diarrhea, loss of taste or smell

Measure: Gut- Lung axis in COVID-19

Time: 2 months

Description: Possible protective effects of minerals and vitamins against COVID-19 respiratory illness

Measure: Protective role of minerals and vitamins in COVID-19 patients

Time: 2 months

Description: Trying to explain the link between non-communicable disease severity and COVID-19 prognosis

Measure: non-communicable diseases and COVID-19

Time: 2 months
10 Online, Home-based, Aerobic Training Program Among Adolescents With Chronic Diseases During COVID-19 Pandemic: A Randomized Controlled Trial

Data show that the coronavirus disease 2019 (COVID-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. In addition, the prevalence of chronic diseases among adolescents has increased in the last years. About 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. In march, 2020, the quarantine was officially implemented in Sao Paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. To mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.

NCT04458246
Conditions
  1. Chronic Disease
  2. Chronic Diseases in Adolescence
  3. Chronic Disease of Immune System
  4. Chronic Kidney Diseases
Interventions
  1. Other: Exercise training group
MeSH:Kidney Diseases Renal Insufficiency, Chronic Immune System Diseases Chronic Disease
HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

Primary Outcomes

Description: Semi structured interview

Measure: Safety and efficacy of a home-based exercise training program

Time: From baseline to 3 months of follow-up

Secondary Outcomes

Description: Semi structured interview

Measure: Patients perceptions during social isolation

Time: From baseline to 3 months of follow-up

Description: Quality of life will be assessed by means of Pediatric Quality of Life inventory (PedsQLTM 4.0)

Measure: Adolescents quality of life

Time: From baseline to 3 months of follow-up

Description: Will be assessed by means of a visual analog scale (from 0 - no disease activity) to 10 - maximum disease activity).

Measure: Disease activity

Time: From baseline to 3 months of follow-up

Description: Will be assessed using the visual analog scale from 0 (very good condition) to 10 (very poor condition).

Measure: Disease overall assessment

Time: From baseline to 3 months of follow-up

Description: Will be assessed by means of Strengths & Difficulties Questionnaires

Measure: Strengths and difficulties

Time: From baseline to 3 months of follow-up
11 Perry Virtual - A Prospective and Observational Rural Health Trial

The principal objective of the study is to determine if patient-empowered, real-time and home- based patient monitoring of vital parameters can lead to: - Reduction in admission rates and improved clinical management of chronically ill patients - Reduction in use of medications - Reported quality of life A minimum of 100 patients will be recruited, monitored and observed over 6 months from home with the Coala Heart Monitor. The study population will be representative of rural, high-risk, Medicare (65+ of age) subjects with chronic conditions and will be recruited by the Perry Community Hospital in Linden, TN.

NCT04483154
Conditions
  1. COPD
  2. Arrhythmia
  3. Murmur, Heart
  4. Chronic Disease
Interventions
  1. Device: Coala Heart Monitor
MeSH:Chronic Disease Heart Murmurs
HPO:Heart murmur

Primary Outcomes

Measure: Reducing admission rates

Time: 6 months

Measure: Reduction in use of medications

Time: 6 months

Description: As measured by Rand-36

Measure: Increased quality of life

Time: 6 months

Measure: Improved clinical management

Time: 6 months

Secondary Outcomes

Measure: Show the value of using Coala Heart Monitor in rural care - patients

Time: 6 months

Description: The cloud-based Coala Care platform enables patient data to be shared and accessed efficiently with affiliated specialists. Show how this helps improve clinical management and healthcare processes.

Measure: Show the value of using Coala Heart Monitor in rural care - providers

Time: 6 months
12 A Student-delivered Community Outreach teleheAlth Program for Covid Education and Health Promotion (COACH)

The purpose of this study is to ensure effective health management among community-living older adults during unprecedented times, such as the current COVID-19 pandemic.

NCT04492527
Conditions
  1. Chronic Disease
  2. Aging
  3. Aging Problems
  4. Health Behavior
  5. Multiple Chronic Conditions
  6. Chronic Illness
  7. Chronic Illnesses, Multiple
  8. Healthy Lifestyle
  9. Healthy Aging
  10. Aging Well
  11. Healthy Life Style
  12. Self-management
  13. Self Care
Interventions
  1. Behavioral: Telehealth coaching sessions
MeSH:Chronic Disease Multiple Chronic Conditions

Primary Outcomes

Description: Health Education Impact Questionnaire (HeiQ) that evaluates health directed behaviour for chronic disease management.

Measure: Change from baseline: Health Directed Behaviour at 2 months

Time: Baseline, Post-intervention (immediately after the 2-month intervention)

Secondary Outcomes

Description: 21-item survey scale that looks at perceived depression, anxiety and stress.

Measure: Depression, Anxiety, Stress Scale

Time: Baseline, Post-intervention (immediately after the 2-month intervention)

Description: 19-item survey that evaluates perceived social support.

Measure: Medical Outcomes Study (MOS): Social Support Survey

Time: Baseline, Post-intervention (immediately after the 2-month session)

Description: Survey scale that evaluates at health-related quality of life.

Measure: Medical Outcomes Study (MOS): Short Form-36

Time: Baseline, Post-intervention (immediately after the 2-month session)

Description: 28-item survey scale that looks at health promotion self-efficacy.

Measure: Self-Rated Abilities for Health Practices Scale

Time: Baseline, Post-intervention (immediately after the 2-month session)

Description: Health Education Impact Questionnaire

Measure: Self-management

Time: Baseline, Post-intervention (immediately after the 2-month session)
13 Assessing People's Hospital Outpatient Appointment Preferences in the United Kingdom

The sustainability of the United Kingdom's National Health Service's (NHS) is threatened immediately by Covid-19 and continually by an increasing prevalence of long-conditions that cannot be cured but can be maintained. Shifting traditional face-to-face outpatient appointments to remote video consultations may help the NHS continue to serve patients efficiently. While much research has examined healthcare providers' attitudes and beliefs about remote video consultations, less has attempted to understand how NHS service providers should invite patients to attend them. The present study examines how the framing of an invitation to attend a hospital outpatient appointment by video influences the proportion of people who agree to attend by video. It also explores some of the barriers and facilitators people may experience to attending appointments by video across diagnostic complexities and age groups. The results of this study should help hospitals better present patients with the option to attend video consultations where appropriate, and provide support to mitigate common barriers to people's willingness to give video consultations a go.

NCT04536259
Conditions
  1. Hospital Outpatient Clinics
  2. Chronic Disease
Interventions
  1. Behavioral: Video Default
  2. Behavioral: In-Person Default
  3. Behavioral: Active Choice
MeSH:Chronic Disease

Primary Outcomes

Description: Participants responses will indicate whether they would prefer a video or in-person appointment.

Measure: Response to the outpatient invitation

Time: One day

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook